Epigenomic dysfunction at 16q24.1 ? vascular defects and perinatal consequences. ABSTRACT Heterozygous genomic deletions and point mutations in the FOXF1 cause Alveolar Capillary Dysplasia with Misalignment of Pulmonary Veins (ACDMPV), a neonatally lethal developmental lung disease. The vast majority of ACDMPV patients have additional defects involving heart, gastrointestinal, or genitourinary systems. The mesenchymal FOXF1 transcription factor expressed in the endothelial and smooth muscle cells plays an important role in epithelium-mesenchyme signaling, as a downstream target of Sonic hedgehog pathway. We accumulated the largest collection of ACDMPV samples in the world (N~145 families). Recently, we found that genomic deletions mapping in a protein-coding gene desert ~270 kb upstream to FOXF1 and leaving it intact manifest with the full ACDMPV phenotype. These deletions enabled us to define an ~60 kb tissue-specific enhancer region harboring long non-coding RNAs (lncRNAs), LINC01081 and LINC01082, that are expressed in fetal lungs. Another lncRNA, FENDRR that maps 1.7 kb upstream of FOXF1 in the opposite orientation and likely utilizes the same bi-directional promoter as FOXF1, interacts with chromatin-modifying complex (PRC) 2 to regulate gene expression. Interestingly, homozygous loss of Fendrr, leaving Foxf1 intact, leads to lethal defects of lungs and heart in mouse neonates. Importantly, we found that the FOXF1 locus is imprinted, likely using these lncRNAs; 31/32 of the characterized genomic deletions arose de novo on maternal chromosome 16q24.1. Trisomy 16 in humans, resulting from maternal meiosis I nondisjunction, is the most common prenatal trisomy (>1% of all pregnancies) and lethal unless rescued early embryonically. In one-third of such cases, children with maternal UPD(16) manifest IUGR (attributed to trisomic placenta) and multiple congenital malformations, including heart defects, pulmonary hypoplasia, tracheosophageal fistula, gut malrotation, absent gall bladder, renal agenesis, hydronephrosis, imperforate anus, and single umbilical artery. Interestingly, all the above clinical features, except IUGR, are observed in the vast majority of children with ACDMPV. In contrast, relatively normal phenotype was reported in few patients with paternal UPD(16), and imprinted gene(s) on chromosome 16 were suggested as causative for maternal UPD(16) phenotype. We hypothesize that FOXF1 enhancer and lncRNAs play an important role in genomic imprinting at 16q24.1, which may be responsible for the key features of maternal UPD(16).
In aim 1, we will study the role of genomic imprinting of the FOXF1 locus in ACDMPV and UPD(16).
In aim 2, we will analyze the function of the FOXF1 enhancer, including the overlapping lncRNAs.
In aim 3, we will investigate the function of FENDRR in development and disease of heart, lung, and placenta. The proposed studies would provide a better understanding of the function of distant tissue-specific enhancers in genomic imprinting and the development and disease. This proposal would also elucidate the role of lncRNAs in enhancer function and gene regulation in general, and provide knowledge on this class of promising therapeutic targets.

Public Health Relevance

We will elucidate how tissue-specific distant enhancer in chromosome 16q24.1 including long noncoding RNAs (lncRNAs) regulate expression of FOXF1, the gene responsible for a neonatal diffuse developmental disorder of the lungs, alveolar capillary dysplasia with misalignment of pulmonary veins (ACDMPV), commonly associated with multiple congenital malformations involving the cardiac, gastrointestinal, and genitourinary systems. We will study the role of lncRNAs in genomic imprinting of the FOXF1 locus on chromosome 16q24.1. We will determine whether genomic imprinting at chromosome 16q24.1 is responsible for the phenotype of maternal UPD(16). We will also study the function of lncRNA FENDRR in development of lungs, heart and placenta. LncRNAs are considered promising therapeutic targets and we believe that by manipulating their expression, we may have the potential to correct the lethal phenotype of ACDMPV and UPD(16).

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
5R01HL137203-02
Application #
9488041
Study Section
Pregnancy and Neonatology Study Section (PN)
Program Officer
Lin, Sara
Project Start
2017-05-22
Project End
2021-04-30
Budget Start
2018-05-01
Budget End
2019-04-30
Support Year
2
Fiscal Year
2018
Total Cost
Indirect Cost
Name
Baylor College of Medicine
Department
Genetics
Type
Schools of Medicine
DUNS #
051113330
City
Houston
State
TX
Country
United States
Zip Code
77030